Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Construction Investment International as the sole sponsor, while already being listed on the Shenzhen Stock Exchange [1]. Group 1: Company Overview - Changchun High-tech is a leading innovation-driven pharmaceutical group in China, covering therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine, with capabilities across all major drug registration types in China [4]. - The company has established a competitive and diversified product matrix through a differentiated innovation strategy, leading to strong financial performance and a solid foundation for sustainable growth [4]. - In 2024, the sales revenue from pharmaceutical products is projected to reach RMB 12.7 billion, maintaining over RMB 10 billion for four consecutive years [4]. Group 2: Product Development and Pipeline - Changchun High-tech has developed a strong and diversified product portfolio in areas such as endocrine and metabolic diseases, women's health, immune and respiratory diseases, tumors, vaccines, and traditional Chinese medicine [5]. - The company has successfully launched 13 new drug products, including the first domestically developed shingles vaccine approved in January 2023 and the first innovative biological drug for acute gouty arthritis approved in June 2025 [5]. - As of September 23, 2025, the company has over 40 candidate drugs in clinical stages or submitted for IND applications, including 14 in Phase III clinical trials or NDA stages, showcasing potential for global first-in-class or best-in-class drugs [6]. Group 3: Financial Performance - For the fiscal years 2022 to 2025, the company reported revenues of approximately RMB 12.63 billion, RMB 14.57 billion, RMB 13.47 billion, and RMB 6.64 billion for the first half of 2025, respectively [6][8]. - The net profit for the same periods was approximately RMB 4.22 billion, RMB 4.78 billion, RMB 2.71 billion, and RMB 0.93 billion for the first half of 2025, indicating fluctuations in profitability [6][8].

每经AI快讯，9月29日，港交所文件显示，长春高新（000661）技术产业(集团)股份有限公司向港交所 提交上市申请书，独家保荐人为中信建投（601066）国际。 ...

Core Viewpoint - Changchun High-tech has applied for a listing on the Hong Kong Stock Exchange, indicating its intention to expand its capital market presence and potentially raise funds for future growth [1] Group 1 - The application for listing was officially submitted to the Hong Kong Stock Exchange [1]

长春高新申请香港上市。 ...

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. is strategically positioning itself in the innovative and diversified upgrade of the domestic biopharmaceutical industry, focusing on three key areas: growth hormone, diversified commercialization of innovative products, and international licensing of new drugs [2][10]. Group 1: Innovation and R&D - Innovation is the lifeline for the survival and development of the company, with a strong emphasis on R&D investment and commercialization of innovative results [3][5]. - Changchun High-tech has established a comprehensive innovation system that spans R&D, production, clinical trials, and commercialization, particularly in the field of growth hormones [5][6]. - The company has made significant strides in the growth hormone market, breaking foreign monopolies and developing a complete product line, including the first injectable human growth hormone in China [4][6]. Group 2: Diversification Strategy - The company is transitioning from a reliance on a single product to a diversified innovation strategy to address market competition and internal structural challenges [6][8]. - Changchun High-tech is expanding its business into pediatric care, women's health, and oncology, developing a full-service system in these areas [7][8]. - The company is also enhancing its product pipeline through its subsidiaries, focusing on differentiated advantages and a variety of clinical trials [7][8]. Group 3: Internationalization Efforts - Internationalization is a core strategy for the company, aiming to build a competitive edge in the global biopharmaceutical market [9][10]. - The company has established a strategic framework for international collaboration, focusing on co-developing products that meet global market demands [9][10]. - Changchun High-tech plans to accelerate its internationalization process by issuing H-shares and listing in Hong Kong, enhancing its global competitiveness [10].

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. 長春高新技術產業（集團）股份有限公司 (the "C ...

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容 概不負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. 長春高新技術產業（集團）股份有限公司 （「本公司」） （一家於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。您閱覽本文件，即代 表您知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 於本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處 長登記前，本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要 約或邀請，準投資者務請僅依據將呈交香港公司註冊處註冊的本公司招股章程作出投資決定； 有關文本 ...

Group 1 - The core viewpoint of the news is that Changchun High-tech has seen a significant increase in its stock price, rising by 5.09% to 128.80 CNY per share, with a total market capitalization of 52.542 billion CNY [1] - Changchun High-tech was established on June 10, 1993, and listed on December 18, 1996. The company primarily engages in the research, production, and sales of biopharmaceuticals and traditional Chinese medicine, with a revenue composition of 92.83% from pharmaceuticals, 6.81% from real estate, and 0.36% from services [1] - The trading volume for Changchun High-tech reached 777 million CNY, with a turnover rate of 1.53% [1] Group 2 - According to data, one fund under CITIC Prudential has a significant holding in Changchun High-tech. The CITIC Prudential CSI 800 Pharmaceutical Index (LOF) A (165519) increased its holdings by 2,700 shares in the second quarter, bringing the total to 55,100 shares, which represents 2.18% of the fund's net value [2] - The CITIC Prudential CSI 800 Pharmaceutical Index (LOF) A (165519) was established on January 1, 2021, and has a current size of 235 million CNY. The fund has achieved a return of 28.93% this year, ranking 1892 out of 4220 in its category [2] - The fund manager, Huang Zhi, has been in charge for 7 years and 66 days, with the fund's total asset size at 3.01 billion CNY. The best return during his tenure was 146.63%, while the worst was -20.24% [3]

天风证券研报指出，长春高新与ALK合作，有望开启中国脱敏新时代。本次合作产品包括ALK自主开 发的2款变应原特异性免疫治疗产品和1款用于过敏原诊断的皮肤点刺试剂盒。中国拥有全球尘螨过敏患 者最大的患者人群，但中国过敏免疫疗法市场开发不足、缺乏创新产品。目前接受脱敏治疗的患者数量 不足100万，存在大量未满足临床需求。认为此次合作有望与金赛的生长激素产品形成协同，横向拓展 公司产品线。维持"买入"评级。 ...

Core Viewpoint - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical, has entered into a partnership with Denmark's ALK-Abelló A/S for the exclusive agency rights of three allergy immunotherapy products in mainland China, indicating a strategic move to capture a significant market opportunity in the allergy treatment sector [1] Group 1: Partnership and Product Details - The collaboration allows Jinsai Pharmaceutical to exclusively market ALK's three products in mainland China, with one subcutaneous injection already launched and a sublingual tablet currently in Phase III clinical trials [1] - The partnership is set to last until 2039, suggesting a long-term commitment to developing the allergy treatment market [1] Group 2: Market Potential - China is the largest market for dust mite desensitization therapy, with a total market size exceeding 1.1 billion RMB in 2023 and a compound annual growth rate (CAGR) of 12% over the next three years [1] Group 3: Product Pipeline and R&D Investment - Jinsai Pharmaceutical's Fuxin Qibai monoclonal antibody is the first fully human anti-IL-1β monoclonal antibody in China, expected to be approved by June 2025, addressing a gap in long-acting targeted therapies for gout [1] - Increased R&D investment has enabled Jinsai Pharmaceutical to attract new talent and establish a drug development platform focused on antibody-drug conjugates (ADC) for oncology [1] Group 4: Investment Rating - The company has been given a "Buy" investment rating, reflecting confidence in its growth prospects and strategic initiatives [1]